Related Experiment Videos
Intermittent melphalan in the treatment of essential thrombocytosis with haemorrhage or thrombosis
Abstract:
178 episodes of essential thrombocytosis with symptoms of haemorrhage or thrombosis, were treated in 15 patients with melphalan (5 mg/m2 orally during 4 d). An average reduction in the platelet count of 77% was achieved by oral melphalan in 14 responding patients. 1 patient appeared to be refractory to oral therapy, but a decrease of the thrombocyte count was achieved after intravenous administration of melphalan. All responding patients experienced a relief of the thrombocytosis-associated clinical symptoms. Reduction of the thrombocyte count persisted for 3-4 wk.
Insights
Oral melphalan effectively reduced platelet counts and relieved symptoms in most patients with essential thrombocytosis. Treatment persisted for 3-4 weeks, offering relief from hemorrhage and thrombosis risks.
Area of Science:
- Hematology
- Oncology
Background:
- Essential thrombocytosis is a myeloproliferative neoplasm characterized by elevated platelet counts.
- Symptoms include hemorrhage and thrombosis, necessitating effective treatment strategies.
Purpose of the Study:
- To evaluate the efficacy of melphalan in treating essential thrombocytosis.
- To assess the impact of melphalan on platelet counts and associated clinical symptoms.
Main Methods:
- Fifteen patients with essential thrombocytosis and symptomatic bleeding or clotting were treated with oral melphalan (5 mg/m2 for 4 days).
- Platelet counts and clinical symptoms were monitored throughout the treatment period.
Main Results:
- An average platelet count reduction of 77% was observed in 14 out of 15 patients receiving oral melphalan.
- All responding patients reported relief from thrombocytosis-associated symptoms.
- One patient refractory to oral melphalan showed a decrease in thrombocyte count after intravenous administration.
- The reduction in thrombocyte count persisted for 3-4 weeks.
Conclusions:
- Oral melphalan is an effective treatment for essential thrombocytosis, leading to significant reductions in platelet counts.
- Melphalan administration, both oral and intravenous, provides relief from clinical symptoms associated with thrombocytosis.
- The therapeutic effect of melphalan on platelet count reduction is sustained for several weeks.